Bio/pharmaceutical – why we use this term

Bio/pharmaceutical here includes both small molecule drugs and biomolecular drugs (recombinant proteins, monoclonal antibodies) and is intended to include companies that pursue both types of agents as opposed to the so-called biopharmaceutical companies who specialize in therapies based on protein agents.

Those who work on biomolecular drugs (also called biologics) will readily note the differences in the processes at each stage in Discovery and Development. Indeed, the processes that are unique to the discovery and development of biomolecular drugs change the success rates of at least some of the stages, most noticeable in Discovery, as well as the reasons for failure, and project cycle times. In this website we will endeavor to note those differences where they are known at least in a qualitative sense.